COVID-19 (S Protein) is under clinical development by Vaxart and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how COVID-19 (S Protein)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COVID-19 (S Protein) overview
Vaccine candidates are under development for the prevention of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of variant strains, including the South African viral strain and omicron variant. The vaccine candidates are formulated as the enteric-coated tablet and administered by oral route. It is a recombinant adenoviral-vector based vaccine (VXA-COV2-1.1-S) expressing a SARS-CoV-2 antigen and dsRNA adjuvant. It is being developed based on VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform.
Vaxart overview
Vaxart, formerly Aviragen Therapeutics, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, using state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines and design recombinant vaccines for new indications. The company is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. It is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer and dysplasia caused by human papilloma virus (HPV). Vaxart is headquartered in San Francisco, California, the US.
For a complete picture of COVID-19 (S Protein)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
